Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate
Identifieur interne : 003149 ( Main/Exploration ); précédent : 003148; suivant : 003150Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate
Auteurs : F. Porzsolt ; D. Messerer [Allemagne] ; R. Hautmann ; A. Gottwald ; H. Sparwasser ; K. Stockamp ; W. Aulitzky [Autriche] ; J. G. Moormann ; K. Schumacher [Allemagne] ; H. Rasche ; U. Papendick ; W. SchremlSource :
- Journal of Cancer Research and Clinical Oncology [ 0171-5216 ] ; 1988-02-01.
Abstract
Summary: The response rates in metastatic renal cell cancer (RCC) after chemotherapy, hormonal treatment, or immunotherapy rarely exceed 15%. Recently, interferon alpha (IFNα) was used for treatment of this disease in several studies which also demonstrated response rates of 15%. In order to test whether IFN therapy combined with hormones would result in higher response rates we compared single agent IFN therapy with a combined therapy of rIFNα 2C plus medroxyprogesterone acetate (MPA) in a randomized multicenter trial. The rIFNα 2C (2MU) was given s.c. 5 times per week for 8–12 weeks and subsequently once weekly until week 48. In the combined treatment, 750 mg MPA was given p. o. daily until week 48 in addition to the IFN as described. The overall response rate in 93 evaluable patients was 5.4%, corresponding to 2 complete and 3 partial responses. Median survival was 7 months in both treatment groups. These data confirm the ineffectivity of low IFN doses for treatment of RCC. The low response rate is not increased by addition of MPA to IFN. The analysis of other IFN studies suggests that not only IFN doses but also IFN sources may influence response rates in metastatic RCC.
Url:
DOI: 10.1007/BF00390492
Affiliations:
- Allemagne, Autriche
- Bade-Wurtemberg, Bavière, District de Haute-Bavière, District de Stuttgart
- Munich, Stuttgart
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001241
- to stream Istex, to step Curation: 001129
- to stream Istex, to step Checkpoint: 001644
- to stream Main, to step Merge: 003780
- to stream Main, to step Curation: 003149
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate</title><author><name sortKey="Porzsolt, F" sort="Porzsolt, F" uniqKey="Porzsolt F" first="F." last="Porzsolt">F. Porzsolt</name></author><author><name sortKey="Messerer, D" sort="Messerer, D" uniqKey="Messerer D" first="D." last="Messerer">D. Messerer</name></author><author><name sortKey="Hautmann, R" sort="Hautmann, R" uniqKey="Hautmann R" first="R." last="Hautmann">R. Hautmann</name></author><author><name sortKey="Gottwald, A" sort="Gottwald, A" uniqKey="Gottwald A" first="A." last="Gottwald">A. Gottwald</name></author><author><name sortKey="Sparwasser, H" sort="Sparwasser, H" uniqKey="Sparwasser H" first="H." last="Sparwasser">H. Sparwasser</name></author><author><name sortKey="Stockamp, K" sort="Stockamp, K" uniqKey="Stockamp K" first="K." last="Stockamp">K. Stockamp</name></author><author><name sortKey="Aulitzky, W" sort="Aulitzky, W" uniqKey="Aulitzky W" first="W." last="Aulitzky">W. Aulitzky</name></author><author><name sortKey="Moormann, J G" sort="Moormann, J G" uniqKey="Moormann J" first="J. G." last="Moormann">J. G. Moormann</name></author><author><name sortKey="Schumacher, K" sort="Schumacher, K" uniqKey="Schumacher K" first="K." last="Schumacher">K. Schumacher</name></author><author><name sortKey="Rasche, H" sort="Rasche, H" uniqKey="Rasche H" first="H." last="Rasche">H. Rasche</name></author><author><name sortKey="Papendick, U" sort="Papendick, U" uniqKey="Papendick U" first="U." last="Papendick">U. Papendick</name></author><author><name sortKey="Schreml, W" sort="Schreml, W" uniqKey="Schreml W" first="W." last="Schreml">W. Schreml</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4D502F7732915A9366DF4F1E15EF2A675D3B2A58</idno><date when="1988" year="1988">1988</date><idno type="doi">10.1007/BF00390492</idno><idno type="url">https://api.istex.fr/document/4D502F7732915A9366DF4F1E15EF2A675D3B2A58/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001241</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001241</idno><idno type="wicri:Area/Istex/Curation">001129</idno><idno type="wicri:Area/Istex/Checkpoint">001644</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001644</idno><idno type="wicri:doubleKey">0171-5216:1988:Porzsolt F:treatment:of:advanced</idno><idno type="wicri:Area/Main/Merge">003780</idno><idno type="wicri:Area/Main/Curation">003149</idno><idno type="wicri:Area/Main/Exploration">003149</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate</title><author><name sortKey="Porzsolt, F" sort="Porzsolt, F" uniqKey="Porzsolt F" first="F." last="Porzsolt">F. Porzsolt</name><affiliation><wicri:noCountry code="subField">Ulm</wicri:noCountry></affiliation></author><author><name sortKey="Messerer, D" sort="Messerer, D" uniqKey="Messerer D" first="D." last="Messerer">D. Messerer</name><affiliation wicri:level="3"><country>Allemagne</country><placeName><settlement type="city">Munich</settlement><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region></placeName><wicri:orgArea>Biometrisches Zentrum für Therapiestudien München, D-8000</wicri:orgArea></affiliation></author><author><name sortKey="Hautmann, R" sort="Hautmann, R" uniqKey="Hautmann R" first="R." last="Hautmann">R. Hautmann</name><affiliation><wicri:noCountry code="subField">Ulm</wicri:noCountry></affiliation></author><author><name sortKey="Gottwald, A" sort="Gottwald, A" uniqKey="Gottwald A" first="A." last="Gottwald">A. Gottwald</name><affiliation><wicri:noCountry code="subField">Ulm</wicri:noCountry></affiliation></author><author><name sortKey="Sparwasser, H" sort="Sparwasser, H" uniqKey="Sparwasser H" first="H." last="Sparwasser">H. Sparwasser</name><affiliation><wicri:noCountry code="subField">Koblenz</wicri:noCountry></affiliation></author><author><name sortKey="Stockamp, K" sort="Stockamp, K" uniqKey="Stockamp K" first="K." last="Stockamp">K. Stockamp</name><affiliation><wicri:noCountry code="subField">Ludwigshafen</wicri:noCountry></affiliation></author><author><name sortKey="Aulitzky, W" sort="Aulitzky, W" uniqKey="Aulitzky W" first="W." last="Aulitzky">W. Aulitzky</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Urologische Klinik Salzburg, Salzburg</wicri:regionArea><wicri:noRegion>Salzburg</wicri:noRegion></affiliation></author><author><name sortKey="Moormann, J G" sort="Moormann, J G" uniqKey="Moormann J" first="J. G." last="Moormann">J. G. Moormann</name><affiliation><wicri:noCountry code="subField">Trier</wicri:noCountry></affiliation></author><author><name sortKey="Schumacher, K" sort="Schumacher, K" uniqKey="Schumacher K" first="K." last="Schumacher">K. Schumacher</name><affiliation wicri:level="3"><country>Allemagne</country><placeName><settlement type="city">Stuttgart</settlement><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Stuttgart</region></placeName><wicri:orgArea>Robert-Bosch-Krankenhaus Stuttgart, D-7000</wicri:orgArea></affiliation></author><author><name sortKey="Rasche, H" sort="Rasche, H" uniqKey="Rasche H" first="H." last="Rasche">H. Rasche</name><affiliation><wicri:noCountry code="subField">Bremen</wicri:noCountry></affiliation></author><author><name sortKey="Papendick, U" sort="Papendick, U" uniqKey="Papendick U" first="U." last="Papendick">U. Papendick</name><affiliation><wicri:noCountry code="subField">Ingelheim</wicri:noCountry></affiliation></author><author><name sortKey="Schreml, W" sort="Schreml, W" uniqKey="Schreml W" first="W." last="Schreml">W. Schreml</name><affiliation><wicri:noCountry code="subField">Ulm</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Cancer Research and Clinical Oncology</title><title level="j" type="abbrev">J Cancer Res Clin Oncol</title><idno type="ISSN">0171-5216</idno><idno type="eISSN">1432-1335</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1988-02-01">1988-02-01</date><biblScope unit="volume">114</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="95">95</biblScope><biblScope unit="page" to="100">100</biblScope></imprint><idno type="ISSN">0171-5216</idno></series><idno type="istex">4D502F7732915A9366DF4F1E15EF2A675D3B2A58</idno><idno type="DOI">10.1007/BF00390492</idno><idno type="ArticleID">BF00390492</idno><idno type="ArticleID">Art16</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0171-5216</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: The response rates in metastatic renal cell cancer (RCC) after chemotherapy, hormonal treatment, or immunotherapy rarely exceed 15%. Recently, interferon alpha (IFNα) was used for treatment of this disease in several studies which also demonstrated response rates of 15%. In order to test whether IFN therapy combined with hormones would result in higher response rates we compared single agent IFN therapy with a combined therapy of rIFNα 2C plus medroxyprogesterone acetate (MPA) in a randomized multicenter trial. The rIFNα 2C (2MU) was given s.c. 5 times per week for 8–12 weeks and subsequently once weekly until week 48. In the combined treatment, 750 mg MPA was given p. o. daily until week 48 in addition to the IFN as described. The overall response rate in 93 evaluable patients was 5.4%, corresponding to 2 complete and 3 partial responses. Median survival was 7 months in both treatment groups. These data confirm the ineffectivity of low IFN doses for treatment of RCC. The low response rate is not increased by addition of MPA to IFN. The analysis of other IFN studies suggests that not only IFN doses but also IFN sources may influence response rates in metastatic RCC.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Autriche</li></country><region><li>Bade-Wurtemberg</li><li>Bavière</li><li>District de Haute-Bavière</li><li>District de Stuttgart</li></region><settlement><li>Munich</li><li>Stuttgart</li></settlement></list><tree><noCountry><name sortKey="Gottwald, A" sort="Gottwald, A" uniqKey="Gottwald A" first="A." last="Gottwald">A. Gottwald</name><name sortKey="Hautmann, R" sort="Hautmann, R" uniqKey="Hautmann R" first="R." last="Hautmann">R. Hautmann</name><name sortKey="Moormann, J G" sort="Moormann, J G" uniqKey="Moormann J" first="J. G." last="Moormann">J. G. Moormann</name><name sortKey="Papendick, U" sort="Papendick, U" uniqKey="Papendick U" first="U." last="Papendick">U. Papendick</name><name sortKey="Porzsolt, F" sort="Porzsolt, F" uniqKey="Porzsolt F" first="F." last="Porzsolt">F. Porzsolt</name><name sortKey="Rasche, H" sort="Rasche, H" uniqKey="Rasche H" first="H." last="Rasche">H. Rasche</name><name sortKey="Schreml, W" sort="Schreml, W" uniqKey="Schreml W" first="W." last="Schreml">W. Schreml</name><name sortKey="Sparwasser, H" sort="Sparwasser, H" uniqKey="Sparwasser H" first="H." last="Sparwasser">H. Sparwasser</name><name sortKey="Stockamp, K" sort="Stockamp, K" uniqKey="Stockamp K" first="K." last="Stockamp">K. Stockamp</name></noCountry><country name="Allemagne"><region name="Bavière"><name sortKey="Messerer, D" sort="Messerer, D" uniqKey="Messerer D" first="D." last="Messerer">D. Messerer</name></region><name sortKey="Schumacher, K" sort="Schumacher, K" uniqKey="Schumacher K" first="K." last="Schumacher">K. Schumacher</name></country><country name="Autriche"><noRegion><name sortKey="Aulitzky, W" sort="Aulitzky, W" uniqKey="Aulitzky W" first="W." last="Aulitzky">W. Aulitzky</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003149 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003149 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Rhénanie
|area= UnivTrevesV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4D502F7732915A9366DF4F1E15EF2A675D3B2A58
|texte= Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate
}}
| This area was generated with Dilib version V0.6.31. |  |